Glympse 将在 2022 年 AASLD 肝脏会议上展示肝细胞癌的灵敏检测

StephenW

Glympse 将在 2022 年 AASLD 肝脏会议上展示肝细胞癌的灵敏检测数据
（PRNewsfoto/Glympse Bio）

新闻提供者
Glympse 生物

美国东部时间 2022 年 10 月 25 日 08:00
分享这篇文章

-数据展示了测量蛋白酶活性的新平台，可准确区分肝细胞癌 (HCC) 患者与无 HCC 的肝硬化患者，单独或与甲胎蛋白 (AFP) 生物标志物血液检测相结合

马萨诸塞州剑桥，2022 年 10 月 25 日 /美通社/ -- Glympse 是一家开发革命性技术来诊断和监测疾病的生物技术公司，今天宣布将展示一张海报，展示其新型蛋白酶生物传感器诊断平台可以检测肝细胞癌（ HCC) 在美国肝病研究协会 (AASLD) 2022 年肝脏会议上，于 2022 年 11 月 4 日至 8 日在华盛顿特区举行。

HCC 的发病率正在上升，预计这一趋势将持续到 2030 年。目前的 HCC 监测方法，包括超声和/或甲胎蛋白 (AFP) 生物标志物血液检测，未能识别出超过三分之一的早期 HCC案例。 Glympse 最近公布的早期数据表明，其新型非侵入性生物传感器组可测量血液样本中的蛋白酶活性，能够将 HCC 患者与健康对照组 (AUC > 0.94) 和没有 HCC 的肝硬化患者区分开来 (AUC = 0.93)。

在 AASLD 上，Glympse 将展示一张海报，将其生物传感器面板与 54 名 HCC 患者和 23 名肝硬化但没有 HCC 的患者的样本中的 AFP 血液检测进行比较。 Glympse 检测在 30 名 AFP 水平低于 20 ng/mL 的患者中的 22 名中检测到 HCC，这表明 AFP 不能诊断的 HCC 患者的潜在诊断。 Glympse 检测和 AFP 生物标志物检测（AFP ≥ 20 ng/mL）相结合，表明 AUC = 0.90 可区分 HCC 和肝硬化患者。

“迫切需要创新的早期 HCC 检测技术，”德克萨斯大学西南医学中心肝肿瘤项目医学主任兼肝病学临床主任 Amit Singal 医学博士说。 “这些数据表明，一种新的 HCC 检测方法（如测量蛋白酶活性）可能会增加我们未来的监测资源。”

“这些令人鼓舞的数据表明，即使常用的标记物为阴性，Glympse 蛋白酶活性测定也可能准确检测患者的 HCC。这突出了它作为一种宝贵的监测工具的潜力，”医学博士 Tram Tran 说。瞥见。 “随着 HCC 病例数的持续增长，早期发现对于我们对抗这种疾病的能力至关重要。我们期待在 AASLD 上展示这些数据，并与科学界就这项重要研究进行交流。”

关于海报展示的信息可以在下面找到。

标题：与标准 AFP 相比，使用新型蛋白酶测定法准确诊断肝硬化患者的 HCC
提交人：Tram Tran，医学博士
时间/日期：11 月 7 日，星期一，下午 1:00 – 2:00美东时间
摘要#：4415
关于 Glympse

Glympse 是一家专注于优化疾病诊断和监测的生物技术公司。该公司正在开发生物传感器技术，通过简单的抽血，可以测量与疾病进展有关的蛋白质的活性。使用专有的机器学习算法，Glympse 生物传感器蛋白酶活性测定数据用于生成有关疾病的实时信息。该技术的主要适应症是非酒精性脂肪性肝炎 (NASH)，这是一种最严重的非酒精性脂肪肝疾病，目前通过侵入性肝活检程序进行诊断。欲了解更多信息，请访问 www.glympsebio.com。

投资者联络
马修·纳瓦罗
Glympse
[email protected]

StephenW

Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022
(PRNewsfoto/Glympse Bio)

News provided by
Glympse Bio

Oct 25, 2022, 08:00 ET
Share this article

-Data demonstrating novel platform to measure protease activity accurately differentiates patients with hepatocellular carcinoma (HCC) vs. patients with liver cirrhosis without HCC, alone or in combination with alpha-fetoprotein (AFP) biomarker blood test

CAMBRIDGE, Mass., Oct. 25, 2022 /PRNewswire/ -- Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced that it will present a poster demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2022, being held in Washington, D.C., from Nov. 4-8, 2022.

The incidence of HCC is rising and is projected to continue this trend through 2030. Current methods of HCC surveillance, including ultrasound and/or the alpha-fetoprotein (AFP) biomarker blood test, fail to identify over one-third of early-stage HCC cases. Glympse recently presented early data demonstrating that its panel of novel, non-invasive biosensors, which measure protease activity from a blood sample, was able to differentiate patients with HCC from healthy controls (AUC > 0.94) and from cirrhosis patients without HCC (AUC = 0.93).

At AASLD, Glympse will present a poster evaluating its biosensor panel in comparison to the AFP blood test in samples from 54 patients with HCC and 23 patients with liver cirrhosis but without HCC. The Glympse assay detected HCC in 22 of 30 patients with AFP levels below 20 ng/mL, suggesting the potential diagnosis of HCC patients in whom AFP is not diagnostic. In combination, the Glympse assay and AFP biomarker test (AFP ≥ 20 ng/mL) demonstrated an AUC = 0.90 in differentiating HCC and cirrhosis patients.

"Innovative, early HCC detection techniques are urgently needed," said Amit Singal, M.D., Medical Director of the Liver Tumor Program and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. "These data demonstrate that a novel approach for HCC detection like measuring protease activity may add to our future resources for surveillance."

"These encouraging data demonstrate that the Glympse protease activity assay may accurately be able to detect HCC in patients, even if commonly used markers are negative. This highlights its potential as an invaluable surveillance tool," said Tram Tran, M.D., Chief Medical Officer of Glympse. "As HCC case numbers continue to grow, early detection is essential to our ability to combat this disease. We look forward to presenting this data at AASLD and engaging with the scientific community about this important research."

Information regarding the poster presentation can be found below.

Title: Accurate diagnosis of HCC in cirrhotic patients with a novel protease assay compared to standard AFP
Presented By: Tram Tran, M.D.
Time/Date: Monday, Nov. 7, 1:00 – 2:00 p.m. EST
Abstract #: 4415
About Glympse

Glympse is a biotechnology company focused on optimizing disease diagnosis and monitoring. The company is developing biosensor technology that, from a simple blood draw, can measure the activity of proteins that are uniquely involved in the progression of disease. Using proprietary machine learning algorithms, the Glympse biosensor protease activity assay data is used to generate real-time information about the disease. The lead indication for this technology is non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease, which is currently diagnosed through an invasive liver biopsy procedure. For more information, please visit www.glympsebio.com.

Investor Contact
Matthew Navarro
Glympse
[email protected]